Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
1.
Andrology ; 4(3): 456-64, 2016 05.
Article in English | MEDLINE | ID: mdl-27027567

ABSTRACT

UNLABELLED: This study was aimed to assess the antioxidant enzymatic and non-enzymatic compounds in semen of infertile men. Seventy-four infertile patients were grouped according to their clinical diagnosis: genitourinary infection, varicocele, idiopathic infertility. Semen samples of fertile men represent the control. Semen characteristics were evaluated by light and transmission electron microscopy (TEM). TEM data was quantified with a mathematical formula, which provides numerical scores. Spectrophotometric and HPLC methods were used to measure the amount of reduced (GSH), oxidised glutathione (GSSG), ascorbic acid (AA) and malondialdehyde (MDA, marker of lipid peroxidation) and the activity of glutathione reductase, catalase (CAT), glutathione peroxidase. Infertile groups showed significantly decreased values of sperm parameters vs. CONTROLS: In infection and varicocele groups, the seminal MDA levels were significantly increased when compared to controls (p < 0.001), indicating an alteration of oxidative status and a peroxidative damage. In infection and varicocele groups, AA levels were reduced (p < 0.05) vs. control; in the varicocele group, the GSH levels were also decreased (p < 0.05). Significantly higher CAT activity was observed in infection and varicocele groups vs. fertile men (p < 0.001 and p < 0.05 respectively). The GSH/GSSG ratio was significantly decreased in varicocele and idiopathic infertility groups vs. control (p < 0.01). The study of the alteration of a single parameter of oxidative stress or of the antioxidant system may not have a relevant clinical value to estimate male fertilising potential and the background of infertility causes, since complex and multifactorial mechanisms are involved in different pathologies. In our study, each pathology is characterised by a definite pattern of markers such as MDA and enzymatic and non-enzymatic antioxidant compounds. In the different pathologies related to infertility, the identification of the complex of involved parameters could be useful in the diagnosis, prognosis and in the choice of a possible treatment such as specific antioxidant supplements.


Subject(s)
Infertility, Male/metabolism , Oxidative Stress/physiology , Semen/metabolism , Urinary Tract Infections/metabolism , Varicocele/metabolism , Adult , Ascorbic Acid/metabolism , Biomarkers/metabolism , Catalase/metabolism , Glutathione/metabolism , Humans , Infertility, Male/pathology , Lipid Peroxidation , Male , Malondialdehyde/metabolism , Spermatozoa/metabolism , Urinary Tract Infections/pathology , Varicocele/pathology , Young Adult
2.
Med Oncol ; 32(3): 52, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25636506

ABSTRACT

The aim of this paper was to evaluate the activity and tolerability of weekly docetaxel (D) combined with weekly epirubicin (EPI) in patients with advanced castrate-resistant prostate cancer (CRPC) previously exposed to D and abiraterone acetate (AA). Locally advanced or metastatic CRPC patients with 0-2 performance status, who had progressed after D and AA therapy, were included in the study. Previous treatment with chemotherapy agent cabazitaxel was also admitted. Treatment consisted of D 30 mg/m(2) intravenously (i.v.) and EPI 30 mg/m(2) i.v., every week (D/EPI). Chemotherapy was administered until disease progression or unacceptable toxicity. In our institution, twenty-six patients received D/EPI: their median age was 72 years (range 59-83 years). Twenty-three (88.5%) patients had bone metastases. A decrease in PSA levels ≥50% was observed in seven patients (26.9%, 95% CI: 0.11-0.47); of these, five had achieved a ≥50% PSA response during prior first-line D and six had achieved a PSA response during prior AA Among the subjects who were symptomatic at baseline, pain was reduced in nine patients (38.1%) with a significant decrease in analgesic use. Median progression-free survival was 4.4 months (95% CI, 3-5.2), and median overall survival was 10.7 months (95% CI, 8.9-18.4). Treatment was well tolerated and no grade 4 toxicities were observed. Our findings suggest that weekly D/EPI is feasible and active in heavily pretreated advanced CRPC patients and seem to support the hypothesis that the addition of EPI to D may lead to overcome the resistance to D in a subgroup of patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Prostatic Neoplasms, Castration-Resistant/drug therapy , Abiraterone Acetate/administration & dosage , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Docetaxel , Drug Administration Schedule , Drug Resistance, Neoplasm/drug effects , Epirubicin/administration & dosage , Humans , Male , Middle Aged , Prostatic Neoplasms, Castration-Resistant/mortality , Prostatic Neoplasms, Castration-Resistant/pathology , Survival Analysis , Taxoids/administration & dosage , Treatment Outcome
3.
Pharmacol Res ; 64(5): 517-27, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21864684

ABSTRACT

Liver toxicity is one of the consequences of ecstasy (3,4-methylenedioxymethamphetamine MDMA) abuse and hepatocellular damage is reported after MDMA consumption. Various factors probably play a role in ecstasy-induced hepatotoxicity, namely its metabolism, the increased efflux of neurotransmitters, the oxidation of biogenic amines, and hyperthermia. MDMA undergoes extensive hepatic metabolism that involves the production of reactive metabolites which form adducts with intracellular nucleophilic sites. MDMA-induced-TNF-α can promote multiple mechanisms to initiate apoptosis in hepatocytes, activation of pro-apoptotic (BID, SMAC/DIABLO) and inhibition of anti-apoptotic (NF-κB, Bcl-2) proteins. The aim of the present study was to obtain evidence for the oxidative stress mechanism and apoptosis involved in ecstasy-induced hepatotoxicity in rat liver after a single 20 mg/kg, i.p. MDMA administration. Reduced and oxidized glutathione (GSH and GSSG), ascorbic acid (AA), superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GR) and malondialdehyde (MDA), an indicator of lipid peroxidation, were determined in rat liver after 3 and 6h after MDMA treatment. The effect of a single MDMA treatment included decrease of GR and GPx activities (29% and 25%, respectively) and GSH/GSSG ratio (32%) with an increase of MDA (119%) after 3h from ecstasy administration compared to control rats. Liver cytosolic level of AA was increased (32%) after 6 h MDMA treatment. Our results demonstrate a strong positive reaction for TNFα (p<0.001) in hepatocytes and a diffuse apoptotic process in the liver specimens (p<0.001). There was correlation between immunohistochemical results and Western blotting which were quantitatively measured by densitometry, confirming the strong positivity for TNF-α (p<0.001) and NF-κB (p<0.001); weak and intense positivity reactions was confirmed for Bcl-2, SMAC/DIABLO (p<0.001) and BID reactions (p<0.001). The results obtained in the present study suggest that MDMA induces loss of GSH homeostasis, decreases antioxidant enzyme activities, and lipoperoxidation that causes an oxidative stress that accompaines the MDMA-induced apoptosis in liver cells.


Subject(s)
Apoptosis/drug effects , Hallucinogens/toxicity , Lipid Peroxidation/drug effects , Liver/drug effects , N-Methyl-3,4-methylenedioxyamphetamine/toxicity , Oxidative Stress/drug effects , Tumor Necrosis Factor-alpha/metabolism , Animals , Hallucinogens/administration & dosage , Liver/cytology , Male , N-Methyl-3,4-methylenedioxyamphetamine/administration & dosage , Rats , Rats, Wistar
4.
Br J Cancer ; 104(4): 613-9, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-21285986

ABSTRACT

BACKGROUND: This randomised phase II study compared the activity and safety of the combination docetaxel (D)/epirubicin (EPI) with the conventional treatment D/prednisone (P) in advanced castrate-resistant prostate cancer (CRPC) patients. MATERIALS AND METHODS: Patients were randomly assigned to D 30 mg m(-2) as intravenous infusion (i.v.) and EPI 30 mg m(-2) i.v. every week (D/EPI arm), or D 70 mg m(-2) i.v. every 3 weeks and oral P 5 mg twice daily (D/P arm). Chemotherapy was administered until disease progression or unacceptable toxicity. RESULTS: A total of 72 patients were enrolled in the study and randomly assigned to treatment: 37 to D/EPI and 35 to D/P. The median progression-free survival (PFS) was 11.1 months (95% CI 9.2-12.6 months) in the D/EPI arm and 7.7 months (95% CI 5.7-9.4 months) in the D/P arm (P=0.0002). The median survival was 27.3 months (95% CI 22.1-30.8 months) in the D/EPI arm and 19.8 months (95% CI 14.4-24.8 months) in the D/P arm (P=0.003). Both regimens were generally well tolerated. CONCLUSION: The treatment of advanced CRPC with weekly D combined with weekly EPI was feasible and tolerable, and led to superior PFS than the treatment with 3-weekly D and oral P.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Epirubicin/administration & dosage , Prednisone/administration & dosage , Prostatic Neoplasms/drug therapy , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma/pathology , Carcinoma/surgery , Disease Progression , Docetaxel , Drug Administration Schedule , Epirubicin/adverse effects , Feasibility Studies , Humans , Infusions, Intravenous , Male , Middle Aged , Orchiectomy , Prednisone/adverse effects , Prostatic Neoplasms/pathology , Prostatic Neoplasms/surgery , Taxoids , Treatment Failure
5.
Eur Rev Med Pharmacol Sci ; 11(6): 413-7, 2007.
Article in English | MEDLINE | ID: mdl-18306910

ABSTRACT

A pharmacokinetic-pharmacodynamic (PK-PD) model was developed to simulate the plasma profile and the toxicity of vinorelbine after multiple oral dose treatment to humans. The PK drug profile was described by a three-compartment open model linked to a PD model aimed to describe the drug toxicity on the circulating neutrophils. Different dose schedules were simulated holding the total administered dose constant (100 mg p.o. during two weeks): 7.7 mg daily (13 doses), 20 mg every 3 days (5 doses) and 33.3 mg every 6 days (3 doses). The lowest values of the circulating neutrophils were observed after 18 days from the start of the treatment and at nadir the fraction of the circulating neutrophils were 0.733, 0.703 and 0.681 after the three doses in decreasing order. These differences were not clinically significant, however the drug bioavailability, which was fixed to 0.35 in the simulation, might be highly variable among subjects contributing to a large extent to the observed variability in drug toxicity.


Subject(s)
Antineoplastic Agents, Phytogenic/adverse effects , Neutropenia/chemically induced , Neutrophils/drug effects , Vinblastine/analogs & derivatives , Antineoplastic Agents, Phytogenic/pharmacokinetics , Area Under Curve , Biological Availability , Drug Administration Schedule , Humans , Models, Biological , Neutrophils/metabolism , Time Factors , Vinblastine/adverse effects , Vinblastine/pharmacokinetics , Vinorelbine
6.
J Neurosurg Sci ; 50(3): 63-6, 2006 Sep.
Article in English | MEDLINE | ID: mdl-17019386

ABSTRACT

AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon. Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound . This has only been demonstrated experimentally in animals. As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients. METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy. During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample. Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times). In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells. CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.


Subject(s)
Brain Edema/chemically induced , Brain Neoplasms/complications , Brain/drug effects , Glioma/complications , Intracranial Hypertension/chemically induced , Mannitol/adverse effects , Adult , Aged , Blood/drug effects , Blood/metabolism , Blood-Brain Barrier/drug effects , Blood-Brain Barrier/physiology , Brain/pathology , Brain/physiopathology , Brain Edema/physiopathology , Brain Edema/prevention & control , Brain Neoplasms/secondary , Brain Neoplasms/surgery , Diuretics, Osmotic/administration & dosage , Diuretics, Osmotic/adverse effects , Diuretics, Osmotic/pharmacokinetics , Dose-Response Relationship, Drug , Extracellular Fluid/drug effects , Extracellular Fluid/metabolism , Female , Glioma/surgery , Humans , Intracranial Hypertension/physiopathology , Intracranial Hypertension/prevention & control , Male , Mannitol/administration & dosage , Mannitol/pharmacokinetics , Meningeal Neoplasms/complications , Meningeal Neoplasms/surgery , Meningioma/complications , Meningioma/surgery , Middle Aged , Nerve Fibers, Myelinated/drug effects , Nerve Fibers, Myelinated/metabolism , Water-Electrolyte Balance/drug effects , Water-Electrolyte Balance/physiology
7.
Eur J Clin Invest ; 35(8): 499-507, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16101670

ABSTRACT

BACKGROUND: Diets and Omega-3 polyunsaturated fatty acids have been considered as important factors to reduce the risk of cardiovascular and inflammatory diseases, but there are few details on the effects on healthy subjects. The aim of the present study was to examine the variation of several physiological parameters in healthy subjects on different diets supplemented with Omega-3 fatty acids. MATERIALS AND METHODS: The experiment was carried out on 33 subjects divided into four groups according to a double-blind cross-over design with a 1 : 1 ratio for Omega-3 (vs. placebo) and open-label parallel-groups with a 1 : 1 ratio for the Zone diet (vs. the diet suggested by the Italian National Research Institute for Nutrition and Foods). Blood samples were collected at the beginning of the experiment and after 35 (cross-over) and 70 days. The Profile of Mood States test (POMS) was also performed. RESULTS: The arachidonic acid/eicosapentaenoic acid ratio (AA/EPA) was strongly reduced by Omega-3 with a supplementary effect of the diet and in particular the Zone diet. The AA/EPA reduction was correlated with a concomitant decrease of insulin and homocysteine levels. The Zone diet reduced skinfold thickness and body fat percentage and also showed antioxidant effects. The mood state changed after Omega-3 supplementation, with an increased POMS index. This was related to a concomitant reduction of AA/EPA and was particularly evident in the Zone diet. CONCLUSION: AA/EPA and mood state are differently influenced by diet and Omega-3, body fat is particularly reduced by Zone diet, while blood parameters such as triglycerides/HDL ratio, insulin and homocysteine are related to AA/EPA variations. These findings are discussed in terms of differences in the composition of the diets and the influences of Omega-3 on physiological functions.


Subject(s)
Adipose Tissue/physiology , Affect/physiology , Dietary Supplements , Fatty Acids, Omega-3/administration & dosage , Aged , Arachidonic Acid/blood , Ascorbic Acid/blood , Cholesterol/blood , Cross-Over Studies , Diet , Double-Blind Method , Eicosapentaenoic Acid/blood , Female , Homocysteine/blood , Humans , Insulin/blood , Lipid Peroxidation/physiology , Male , Middle Aged , Psychological Tests , Skinfold Thickness , Triglycerides/blood
8.
Eur Rev Med Pharmacol Sci ; 9(6): 361-7, 2005.
Article in English | MEDLINE | ID: mdl-16479741

ABSTRACT

BACKGROUND: Oral squamous cell carcinoma is one of the most common cancers in the world. Reactive oxygen species are postulated to be involved in neoplastic transformation. The antioxidant defence system limits cell injury induced by reactive oxygen species. Oxidative stress occurs when there is an imbalance between the production of reactive oxygen species and a cell's oxidant capacity or when there is a decrease in this capacity. This stress may cause mutagenesis, cytotoxicity and changes in gene expression that initiate or promote carcinogenesis. OBJECTIVES: The present study was conducted to investigate whether tumor tissue and blood of patients with oral squamous cell carcinoma have altered antioxidants levels. METHODS: Levels of antioxidants such as reduced glutathione (GSH) and ascorbic acid (AA) and the activities of antioxidant enzymes superoxide dismutase (SOD), glutathione peroxidase (GPx), glutatione reductase (GR), were estimated in the tumor tissue and blood of 18 oral squamous cell carcinoma patients and in 20 healthy subjects as control. RESULTS: Significantly increased levels of GSH, GPx, GR and AA and significantly decreased activity of SOD were observed in tumor tissue (p < 0.001) and in tumor-free tissue of oral cancer patients as compared with healthy subjects. In contrast, decrease in antioxidants (GSH, GPx, GR and AA p < 0.001, SOD p < 0.05 respectively) was observed in the blood of oral cancer patients, as compared with healthy subjects. CONCLUSION: The low levels of antioxidants in the blood of oral cancer patients may be due to their increased utilization to scavenge lipid peroxides as well as their sequestration by tumor cells. The enhanced antioxidant capacities in tumor tissues can make them less susceptible to oxidative stress, conferring a selective growth advantage on tumor cells. These finding suggest that normalization of the levels of these antioxidants might be used to reduce oral tumor malignancy.


Subject(s)
Antioxidants/metabolism , Carcinoma, Squamous Cell/blood , Mouth Neoplasms/blood , Adolescent , Adult , Aged , Ascorbic Acid/blood , Carcinoma, Squamous Cell/pathology , Female , Glutathione/blood , Glutathione Peroxidase/blood , Glutathione Reductase/blood , Humans , Male , Middle Aged , Mouth Neoplasms/pathology , Superoxide Dismutase/blood , Vitamins/blood
9.
Br J Cancer ; 90(2): 306-9, 2004 Jan 26.
Article in English | MEDLINE | ID: mdl-14735168

ABSTRACT

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/analogs & derivatives , Camptothecin/therapeutic use , Colorectal Neoplasms/drug therapy , Organoplatinum Compounds/therapeutic use , Administration, Oral , Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Camptothecin/administration & dosage , Camptothecin/adverse effects , Colorectal Neoplasms/pathology , Diarrhea/chemically induced , Disease Progression , Drug Administration Schedule , Female , Humans , Infusions, Intravenous , Irinotecan , Leucovorin/administration & dosage , Male , Middle Aged , Neoplasm Metastasis , Organoplatinum Compounds/administration & dosage , Organoplatinum Compounds/adverse effects , Oxaliplatin , Peripheral Nervous System Diseases/chemically induced , Tegafur/administration & dosage , Treatment Outcome , Uracil/administration & dosage
10.
Br J Cancer ; 87(7): 720-5, 2002 Sep 23.
Article in English | MEDLINE | ID: mdl-12232753

ABSTRACT

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m(2) of body surface area. The primary end-point was palliative response, defined as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months (range 1-11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles. The 12- and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1-36). The treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3 thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival.


Subject(s)
Androgens/pharmacology , Drug Resistance, Neoplasm , Epirubicin/administration & dosage , Epirubicin/therapeutic use , Prostatic Neoplasms/drug therapy , Aged , Epirubicin/adverse effects , Humans , Male , Middle Aged , Neoplasm Metastasis/drug therapy , Neoplasm Staging , Pain/drug therapy , Prostatic Neoplasms/pathology , Quality of Life , Survival Rate , Time Factors , Treatment Outcome
11.
Cancer ; 92(6): 1468-74, 2001 Sep 15.
Article in English | MEDLINE | ID: mdl-11745224

ABSTRACT

BACKGROUND: One of the greatest problems in treating advanced prostate carcinoma is monitoring the therapeutic response of bone metastases. As these metastases are mainly osteosclerotic and lead to a markedly increased bone calcium requirement that may give rise to an imbalance in calcium homeostasis, the authors investigated whether changes in calcium balance may be useful for evaluating the response of bone metastases to treatment. METHODS: The study involved 268 prostate carcinoma patients: 142 in Stage A-C2 (International Union Against Cancer [UICC] staging system, 1998) and 126 with bone metastases who had failed to respond to hormone therapy and were receiving chemotherapy. Prostate-specific antigen (PSA), calcium and phosphate metabolism, and the main bone formation and resorption markers were all assayed before and after chemotherapy. RESULTS: Of the 126 patients on chemotherapy, 109 were evaluable for response: according to standard criteria, 25 (23%) had improved, 43 (39.5%) were unchanged, and 41 (37.5%) had worsened. All of the improved and 16 unchanged patients had decreased PSA and bone marker levels and an increased urinary calcium/creatinine ratio (UCa/Cr); the worsened patients had increased PSA and bone marker levels, and their UCa/Cr decreased after only six treatment cycles. PSA and UCa/Cr were the biochemical markers whose changes showed the best agreement with treatment response. CONCLUSION: The UCa/Cr ratio was the most useful marker of clinical response, mainly because it allowed an early decision to continue or to stop chemotherapy. Furthermore, UCa/Cr and PSA together identified a percentage of patients classified as unchanged on the basis of standard criteria but whose condition had actually improved.


Subject(s)
Bone Neoplasms/secondary , Bone Neoplasms/urine , Calcium/urine , Prostatic Neoplasms/pathology , Creatinine/urine , Follow-Up Studies , Humans , Male , Monitoring, Physiologic , Neoplasm Staging , Prostate-Specific Antigen/analysis , Prostatic Neoplasms/drug therapy
12.
Int J Legal Med ; 114(6): 323-30, 2001.
Article in English | MEDLINE | ID: mdl-11508797

ABSTRACT

This study was designed to assess the parameters of myocardial oxidative stress and related cardiac morphological changes following intraperitoneal cocaine exposure in rats. The cardiac levels of reduced glutathione(GSH), oxidised glutathione(GSSG), ascorbic acid (AA), and the production of malondialdehyde (MDA) were measured, as well as the variations of activity in the enzyme systems involved in cell antioxidant defence, glutathione peroxidase (GSH-Px), glutathione reductase (GR) and superoxide dismutase (SOD). After chronic cocaine administration for 30 days GSH was significantly depleted in the heart from 30 min (P < 0.001) to 24 h (P < 0.001) after exposure, and GSSG was increased for a similar time (P < 0.05 at 30 min and P < 0.01 at 24 h). SOD increased during the first hour (P < 0.001), GR and GSH-Px both increased from 30 min to 24 h, and these increases were statistically significant (P < 0.01 and P < 0.001 at 30 min and P < 0.01 and P < 0.001 at 24 h, respectively). The AA levels increased after 1 h (P < 0.01), remaining significantly so for 24 h (P < 0.001) and MDA increased from 30 min to 24 h, all values being highly significant (P < 0.001). The body weight was significantly (P < 0.001) reduced in both cocaine groups (40 mg/kg x 30 days and 40 mg/kg x 10 days + 60 mg/kg x 20 days). The heart weight (P < 0.01) and its percentage of the body weight (P < 0.001) were significantly higher in these two groups than in the controls. Similarly, in the noradrenaline 4 mg/ kg x 30 days group, the body weight was significantly (P < 0.001) reduced and the heart weight (P < 0.01) and its percentage of body weight (P < 0.001) were significantly higher than in the controls. In comparing the cocaine and noradrenaline experiments, the frequency and extent of cardiac lesions obtained with 40 mg/kg x 10 days + 60 mg/kg x 20 days of cocaine were similar to those with 8 mg/kg of noradrenaline at 24 h. In this experimental model, cocaine administration compromised the antioxidant defence system of the heart associated with a significant increase of heart weight and the percentage of body weight.


Subject(s)
Cocaine/adverse effects , Heart/drug effects , Myocardium/metabolism , Oxidative Stress/drug effects , Animals , Apoptosis/drug effects , Ascorbic Acid/metabolism , Dopamine Uptake Inhibitors/adverse effects , Glutathione/metabolism , Kidney Diseases/metabolism , Male , Malondialdehyde/metabolism , Myocardium/enzymology , Rats , Statistics, Nonparametric , Superoxide Dismutase/metabolism , Vasoconstrictor Agents/adverse effects
13.
J Chromatogr B Biomed Appl ; 678(2): 365-8, 1996 Apr 12.
Article in English | MEDLINE | ID: mdl-8738045

ABSTRACT

A simple high-performance liquid chromatographic (HPLC) method for the determination of flufenamic acid in rat plasma is described. After liquid-liquid extraction, the drug is separated by HPLC on a 5-microns octadecylsilica column (Nucleosil C18) with ultraviolet detection at 280 nm. Linear calibration graphs for flufenamic acid were constructed from 0.5 to 15 micrograms/ml. The method has been applied to a pharmacokinetic study in animals.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal , Chromatography, High Pressure Liquid/methods , Flufenamic Acid/blood , Animals , Chromatography, High Pressure Liquid/statistics & numerical data , Flufenamic Acid/pharmacokinetics , Rats , Sensitivity and Specificity
14.
Environ Health Perspect ; 102 Suppl 9: 63-4, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7698087

ABSTRACT

Glutathione (GSH) levels in rat testis and lung after oral administration (3 g/kg) of acetaminophen (APAP) were studied. At the administered dose APAP is present in each organ and influences the GSH levels. APAP value of 114 micrograms/g was obtained in testis at 6 hr (peak time); in the lung the Cmax was 92 mu/g at 8 hr and this value lasted several hours longer than that in testis. GSH levels are also affected differently in the organs studied after APAP administration; the lungs seem to be the primary organ undergoing the depleting action of APAP. This process could not only cause toxicity, but also predispose those organs to the action of toxic compounds responsible for specific pathologies.


Subject(s)
Acetaminophen/pharmacology , Glutathione/metabolism , Lung/metabolism , Testis/metabolism , Acetaminophen/administration & dosage , Administration, Oral , Animals , Glutathione/drug effects , Male , Rats , Rats, Wistar , Time Factors
15.
J Chromatogr ; 614(1): 103-8, 1993 Apr 21.
Article in English | MEDLINE | ID: mdl-8496269

ABSTRACT

A rapid and precise high-performance liquid chromatographic method for the determination of piroxicam in a variety of biological samples has been developed. A reversed-phase column, isocratic elution and ultraviolet detection were employed. Calibration curves were reproducible and highly linear, with correlation coefficients typically averaging over 0.992. The detection limit of the assay was 100 ng/ml for all biological samples examined (at a signal-to-noise ratio of 3:1). Validation of the method demonstrated a good sensitivity, accuracy and precision. The method has been adopted for a pharmacokinetic study in rats.


Subject(s)
Chromatography, High Pressure Liquid/methods , Muscles/chemistry , Piroxicam/analysis , Skin/chemistry , Animals , Calibration , Male , Piroxicam/blood , Rats , Rats, Wistar , Reproducibility of Results , Spectrophotometry, Ultraviolet
16.
Ann Ist Super Sanita ; 29(3): 387-90, 1993.
Article in English | MEDLINE | ID: mdl-8172455

ABSTRACT

The authors in a previous research verified the effect of administration of three non steroidal antiinflammatory drugs (piroxicam, naproxen, ketoprofen) on the glutathione levels in various organs of rat. On the basis of these researches, the authors study the effect of the same anti-inflammatory drugs on glutathione levels in rat brain, dissected in order to analyze separately the cortex, cerebellum and the remaining part of the brain. The obtained results show that the distribution of the three drugs is not homogeneous in the studied areas and that these three drugs act differently on glutathione levels. These facts let us suppose that piroxicam, naproxen and ketoprofen produce toxic events that are different according to the brain areas we studied.


Subject(s)
Brain Chemistry/drug effects , Glutathione/metabolism , Ketoprofen/pharmacology , Naproxen/pharmacology , Piroxicam/pharmacology , Animals , Cerebellum/drug effects , Cerebellum/metabolism , Cerebral Cortex/drug effects , Cerebral Cortex/metabolism , Ketoprofen/toxicity , Male , Naproxen/toxicity , Piroxicam/toxicity , Rats , Rats, Wistar
17.
J Med Chem ; 35(14): 2697-703, 1992 Jul 10.
Article in English | MEDLINE | ID: mdl-1635066

ABSTRACT

New carbonic anhydrase (EC 4.2.1.1) inhibitors were synthesized as potential drugs for the topical treatment of glaucoma. They were obtained by substituting the acetyl group of acetazolamide and methazolamide with bicarboxylic acids of different chain length (C4-C6). The terminal carboxyl was either kept free or esterified with alcohols of different size (C1-C12). A gamma-aminovaleric derivative was also prepared. All compounds proved active as carbonic anhydrase inhibitors in vitro, with an average IC50 of about 0.5 microM. Some proved also to be topically active in vivo in lowering the artificially elevated intraocular pressure in rabbits. The most active compound, carrying a succinic acid side chain, is the most soluble in aqueous buffers. Its duration of action is about 8 h and it is under evaluation as a topical antiglaucoma drug. It is hypothesized that the duration of action could be longer in compounds having both the same high water solubility and partition coefficient.


Subject(s)
Acetazolamide/analogs & derivatives , Acetazolamide/pharmacology , Carbonic Anhydrase Inhibitors/pharmacology , Intraocular Pressure/drug effects , Acetazolamide/administration & dosage , Administration, Topical , Animals , Carbonic Anhydrase Inhibitors/administration & dosage , Carbonic Anhydrase Inhibitors/chemistry , Glaucoma/drug therapy , Male , Methazolamide/administration & dosage , Methazolamide/analogs & derivatives , Methazolamide/pharmacology , Rabbits , Structure-Activity Relationship
18.
Farmaco ; 47(6): 953-66, 1992 Jun.
Article in English | MEDLINE | ID: mdl-1326978

ABSTRACT

In order to obtain derivatives with simultaneous alpha- and beta-adrenergic blocking activity, compounds having the phenoxypropanolaminic structure of beta-adrenergic blockers have been synthesised, as well as 1,2,4-oxadiazole moiety, which could imitate the imidazolinic nucleus characteristic of drugs acting on alpha-adrenergic receptors. The synthesised compounds have been submitted to alpha and beta receptor binding assays. Some derivatives showed an alpha-adrenoceptor binding activity higher than labetalol and similar to prazosin, but with a poor beta-adrenoceptor binding activity.


Subject(s)
Oxadiazoles/chemical synthesis , Receptors, Adrenergic/drug effects , Animals , Brain Chemistry/drug effects , In Vitro Techniques , Oxadiazoles/pharmacology , Rats , Receptors, Adrenergic, alpha/drug effects , Receptors, Adrenergic, alpha/metabolism , Receptors, Adrenergic, beta/drug effects , Receptors, Adrenergic, beta/metabolism
20.
Agents Actions ; Spec No: C106-8, 1992.
Article in English | MEDLINE | ID: mdl-1442326

ABSTRACT

Since glutathione (GSH) depletion (about 20% of total GSH content) can impair the cell's defence against the toxic actions of drugs and may lead to cell injury and death, we examined the effect of piroxicam, naproxen and ketoprofen on GSH levels in various organs of the rat (brain, eye, liver, stomach, heart, leg adductor muscle). Ketoprofen in brain and leg adductor muscle dramatically decreases the GSH levels, giving rise to potential cellular toxicity.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Brain/drug effects , Glutathione/metabolism , Muscles/drug effects , Animals , Brain/metabolism , Cell Death/drug effects , Eye/drug effects , Eye/metabolism , Gastric Mucosa/metabolism , Heart/drug effects , Ketoprofen/pharmacology , Liver/drug effects , Liver/metabolism , Male , Muscles/metabolism , Naproxen/pharmacology , Piroxicam/pharmacology , Rats , Rats, Wistar , Stomach/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...